Benitec Biopharma Inc. (BNTC)

Market Cap	9.59M
Revenue (ttm)	73,000
Net Income (ttm)	-18.21M
Shares Out	25.81M
EPS (ttm)	-2.17
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	123,656
Open	0.370
Previous Close	0.343
Day's Range	0.330 - 0.384
52-Week Range	0.301 - 3.900
Beta	1.25
Analysts	Buy
Price Target	10.20 (+2,644.1%)
Earnings Date	Nov 14, 2022

About BNTC

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

• Industry: Biotechnology
• Founded: 1995
• Employees: 18
• Stock Exchange: NASDAQ
• Ticker Symbol: BNTC

Full Company Profile

Financial Performance

In 2022, BNTC's revenue was 73,000, an increase of 23.73% compared to the previous year's 59,000. Losses were -18.21 million, 31.2% more than in 2021.

Financial numbers in AUD Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for BNTC stock is "Buy." The 12-month stock price forecast is 10.2, which is an increase of 2,644.15% from the latest price.

Price Target

$10.2

(2,644.15% upside)

Analyst Consensus: Buy

Stock Forecasts